Financial Assistance
Newsletter Sign-up
Need Appointment
Contact Us
About Us

Rush University
For Physicians
For Rush Employees
For Students
Bill Payment Center
Rotate
<< Previous | New Search | Return to Search Results | Next >>

Stephanie A. Gregory, MD

Stephanie A. Gregory, MD
Appointment Request

Or call
(888) 352-RUSH for help arranging an appointment.
Specialty:
  • Hematology
  • Internal Medicine
Board Certification:
  • Hematology
  • Internal Medicine
Faculty Rank: Professor
Medical or Graduate Education: Medical College of Pennsylvania
Residency: Rush University Medical Center - Hematology
Fellowship: Rush University Medical Center - Hematology
Clinical Expertise:
  • Anemia
  • Aplastic anemia
  • Blood disorders, noncancerous
  • Bone marrow biopsy
  • Cutaneous T-cell lymphoma (CTCL)
  • Hairy cell leukemia
  • Hodgkin lymphoma
  • Leukemias, acute and chronic
  • Multiple myeloma
  • Myelodysplastic syndrome (MDS)
  • Myeloproliferative disorders
  • Non-Hodgkin lymphoma
  • Targeted therapy for hematologic cancer
Research Interests:
  • Translational research and targeted therapies for:
  • Lymphomas
  • Acute and chronic leukemias
  • Multiple myelomas
Languages Spoken:
  • English
Google Map
  • Consultants In Hematology
  • Professional Building
  • 1725 W. Harrison St.
  • Suite 1010
  • Chicago, IL  60612
  • Phone: (312) 563-2320
  • Fax: (312) 563-2480
  • View Larger MapDriving Directions

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.

  1. Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial.
    Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Kent Holland H, Winter JN, Mason JR, Fay JW, Rizzieri DA, Hosing CM, Ball ED, Uberti JP, Lazarus HM, Mapara MY, Gregory SA, Timmerman JM, Andorsky D, Or R, Waller EK, Rotem-Yehudar R, Gordon LI
    J. Clin. Oncol.
    2013 Oct 14
    :.
    ENG
  2. Aggressive disease defined by cytogenetics is associated with cytokine dysregulation in CLL/SLL patients.
    Karmali R, Paganessi LA, Frank RR, Jagan S, Larson ML, Venugopal P, Gregory SA, Christopherson KW 2nd.
    J Leukoc Biol. 2013
    2013 Jan
    93(1):161-70. doi: 10.1189/jlb.0612301. Epub 2012 Nov 7.
  3. Successful Treatment of Hepatosplenic T-Cell Lymphoma With ESHAP Followed by Autologous Stem Cell Transplant.
    Chalmers AW, Katz DA, Miller IJ, Gregory SA.
    Clin Adv Hematol Oncol. 2013
    2013 Feb
    11(2):109-13. No abstract available.
  4. Ocular Adnexal MALTomas: Case Series of Patients Treated With Primary Radiation.
    Russell W, Herskovic A, Gessert D, Cohen JA, Rubenstein JB, Gregory SA.
    Clin Adv Hematol Oncol. 2013
    2013 Apr
    11(4):209-14.
  5. CD26 protease inhibition improves functional response of unfractionated cord blood, bone marrow, and mobilized peripheral blood cells to CXCL12/SDF-1.
    Christopherson KW 2nd, Frank RR, Jagan S, Paganessi LA, Gregory SA, Fung HC.
    Exp Hematol. 2012
    2012 Nov
    40(11):945-52. doi: 10.1016/j.exphem.2012.07.009. Epub 2012 Jul 27.
  6. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era.
    Evens AM, Helenowski I, Ramsdale E, Nabhan C, Karmali R, Hanson B, Parsons B, Smith S, Larsen A, McKoy JM, Jovanovic B, Gregory S, Gordon LI, Smith SM.
    Blood. 2012
    2012 Jan 19
    119(3):692-5. doi: 10.1182/blood-2011-09-378414. Epub 2011 Nov 23.
  7. Analysis of very elderly (≥80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome.
    Nabhan C, Smith SM, Helenowski I, Ramsdale E, Parsons B, Karmali R, Feliciano J, Hanson B, Smith S, McKoy J, Larsen A, Hantel A, Gregory S, Evens AM.
    Br J Haematol. 2012
    2012 Jan
    156(2):196-204. doi: 10.1111/j.1365-2141.2011.08934.x. Epub 2011 Nov 16.
  8. Relapsed diffuse large B-cell lymphoma--10 years later.
    Jain S, Shah N, Gregory S.
    Clin Adv Hematol Oncol. 2011
    2011 Sep
    9(9):704-8. No abstract available.
  9. Clinical and laboratory features of myelofibrosis and limitations of current therapies.
    Gregory SA, Mesa RA, Hoffman R, Shammo JM.
    Clin Adv Hematol Oncol. 2011
    2011 Sep
    9(9 Suppl 22):1-16.
  10. Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma.
    Karmali R, Larson ML, Wooldridge JE, Gregory SA, O'Brien T, Shammo JM, Bueschel K, Venugopal P.
    Leuk Lymphoma. 2011
    2011 Nov
    52(11):2097-104. doi: 10.3109/10428194.2011.589549. Epub 2011 Jun 24.
  11. In vivo expansion of the megakaryocyte progenitor cell population in adult CD26-deficient mice.
    Kidd S, Bueso-Ramos C, Jagan S, Paganessi LA, Boggio LN, Fung HC, Gregory SA, Christopherson KW 2nd.
    Exp Hematol. 2011
    2011 May
    39(5):580-590.e1. doi: 10.1016/j.exphem.2011.01.012. Epub 2011 Feb 1.
  12. Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report.
    Witzig TE, Fishkin P, Gordon LI, Gregory SA, Jacobs S, Macklis R, McLaughlin P, Press O, Zelenetz AD.
    Leuk Lymphoma. 2011
    2011 Jul
    52(7):1188-99. doi: 10.3109/10428194.2011.570396. Epub 2011 May 23. Review.
  13. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
    Karmali R, Kassar M, Venugopal P, Shammo JM, Fung HC, Bayer R, O'Brien T, Gregory SA.
    Clin Lymphoma Myeloma Leuk. 2011
    2011 Dec
    11(6):467-74. doi: 10.1016/j.clml.2011.04.009. Epub 2011 Jun 22.
  14. Multiple myeloma with multiple extramedullary plasmacytomas.
    Nangia JR, Lakhani AA, Loew JM, Gregory SA.
    Clin Adv Hematol Oncol. 2011
    2011 Aug
    9(8):630-2. No abstract available.
  15. Bendamustine's emerging role in the management of lymphoid malignancies.
    Rummel MJ, Gregory SA.
    Semin Hematol. 2011
    2011 Apr
    48 Suppl 1:S24-36. doi: 10.1053/j.seminhematol.2011.03.004. Review.
  16. Intravascular B-cell lymphoma following nodal diffuse large B-cell lymphoma.
    Katz DA, Miller IJ, Gregory SA.
    Clin Adv Hematol Oncol. 2010
    2010 Sep
    8(9):637-41. No abstract available.
  17. The future of CD20 monoclonal antibody therapy in B-cell malignancies.
    Czuczman MS, Gregory SA.
    Leuk Lymphoma. 2010
    2010 Jun
    51(6):983-94. doi: 10.3109/10428191003717746. Review.
  18. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.
    Evens AM, David KA, Helenowski I, Nelson B, Kaufman D, Kircher SM, Gimelfarb A, Hattersley E, Mauro LA, Jovanovic B, Chadburn A, Stiff P, Winter JN, Mehta J, Van Besien K, Gregory S, Gordon LI, Shammo JM, Smith SE, Smith SM.
    J Clin Oncol. 2010
    2010 Feb 20
    28(6):1038-46. doi: 10.1200/JCO.2009.25.4961. Epub 2010 Jan 19.
  19. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
    Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA.
    Blood. 2010
    2010 Apr 1
    115(13):2578-85. doi: 10.1182/blood-2009-08-236471. Epub 2009 Nov 17.
  20. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.
    de Vos S, Goy A, Dakhil SR, Saleh MN, McLaughlin P, Belt R, Flowers CR, Knapp M, Hart L, Patel-Donnelly D, Glenn M, Gregory SA, Holladay C, Zhang T, Boral AL.
    J Clin Oncol. 2009
    2009 Oct 20
    27(30):5023-30. doi: 10.1200/JCO.2008.17.7980. Epub 2009 Sep 21.
  21. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia.
    Treon SP, Branagan AR, Ioakimidis L, Soumerai JD, Patterson CJ, Turnbull B, Wasi P, Emmanouilides C, Frankel SR, Lister A, Morel P, Matous J, Gregory SA, Kimby E.
    Blood. 2009
    2009 Apr 16
    113(16):3673-8. doi: 10.1182/blood-2008-09-177329. Epub 2008 Nov 17.
  22. Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma.
    Gregory SA, Hohloch K, Gisselbrecht C, Tobinai K, Dreyling M.
    Oncologist. 2009
    2009
    14 Suppl 2:4-16. doi: 10.1634/theoncologist.2009-S2-4.
  23. New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. Summary.
    Bischof Delaloye A, Conti PS, Gisselbrecht C, Gregory SA.
    Oncologist. 2009
    2009
    14 Suppl 2:52-4. doi: 10.1634/theoncologist.2009-S2-52. Review. No abstract available.
  24. New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. Introduction.
    Bischof Delaloye A, Conti PS, Gisselbrecht C, Gregory SA.
    Oncologist. 2009
    2009
    14 Suppl 2:1-3. doi: 10.1634/theoncologist.2009-S2-1. No abstract available.
  25. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G
    Maki G, Hayes GM, Naji A, Tyler T, Carosella ED, Rouas-Freiss N, Gregory SA
    Leukemia
    2008 May
    22(5):998-1006
  26. Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.
    Leonard JP, Gregory SA, Maloney DG, Vose JM, Younes A, Zelenetz AD.
    Clin Adv Hematol Oncol. 2008
    2008 Jun
    6(6):437-45. Review.
  27. Mesenchymal stem cells from the Wharton's jelly of umbilical cord segments provide stromal support for the maintenance of cord blood hematopoietic stem cells during long-term ex vivo culture.
    Bakhshi T, Zabriskie RC, Bodie S, Kidd S, Ramin S, Paganessi LA, Gregory SA, Fung HC, Christopherson KW 2nd.
    Transfusion. 2008
    2008 Dec
    48(12):2638-44. doi: 10.1111/j.1537-2995.2008.01926.x. Epub 2008 Sep 16.
  28. Idiopathic hemophagocytic syndrome with a fulminant clinical course.
    Khandelwal A, Shah NB, Eichenseer P, Welker M, Miller I, Nangia J, Farhat M, Gimelfarb A, Kassar M, Batus M, Gezer S, Shammo J, Gregory S, Fung H, Venugopal P.
    Clin Adv Hematol Oncol. 2008
    2008 Aug
    6(8):587-90. Review. No abstract available.
  29. Localized bone disease as a presentation of hairy cell leukemia.
    Karmali R, Farhat M, Leslie W, McIntire MG, Gregory S.
    Clin Adv Hematol Oncol. 2008
    2008 Apr
    6(4):290-4. No abstract available.
  • (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
  • View Transcript

Find a Doctor | Patient & Visitor Services | Health Information | Clinical Services | Events & Classes | News Room | Clinical Trials | Research at Rush
Nursing at Rush | Work at Rush | Giving to Rush | Directions to Rush | Disclaimer | Privacy Statement
For Physicians | For Rush Employees | For Students | Bill Payment Center | Site Map
© Rush University Medical Center
1653 W. Congress Parkway, Chicago, Illinois 60612